{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:40:02Z","timestamp":1792374002979,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Measurement of serum human epidermal growth factor receptor-2 (HER-2\/\n                      <jats:italic>neu<\/jats:italic>\n                      ) levels might play an essential role as a diagnostic\/screening marker for the early selection of therapeutic approaches and predict prognosis in breast cancer patients. We aimed to undertake a systematic review and meta-analysis focusing on the diagnostic\/screening value of serum HER-2 levels in comparison to routine methods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic search via PubMed, Scopus, Cochrane-Library, and Web of Science databases for human diagnostic studies reporting the levels of serum HER-2 in breast cancer patients, which was confirmed using the histopathological examination. Meta-analyses were carried out for sensitivity, specificity, accuracy, area under the ROC curve (AUC), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen studies entered into this investigation. The meta-analysis indicated the low sensitivity for serum HER2 levels (Sensitivity: 53.05, 95%CI 40.82\u201365.28), but reasonable specificity of 79.27 (95%CI 73.02\u201385.51), accuracy of 72.06 (95%CI 67.04\u201377.08) and AUC of 0.79 (95%CI 0.66\u20130.92). We also found a significant differences for PPV (PPV: 56.18, 95%CI 44.16\u201368.20), NPV (NPV: 76.93, 95%CI 69.56\u201384.31), PLR (PLR: 2.10, 95%CI 1.69\u20132.50) and NLR (NLR: 0.58, 95%CI 0.44\u20130.71).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings revealed that although serum HER-2 levels showed low se  nsitivity for breast cancer diagnosis, its specificity, accuracy and AUC were reasonable. Hence, it seems that the measurement of serum HER-2 levels can play a significant role as a verification test for initial negative screening test results, especially in low-income regions due to its cost-effectiveness and ease of implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07545-2","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T09:03:13Z","timestamp":1604134993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Amir","family":"Shamshirian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Aref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Ebrahimi Warkiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Heydari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Razavi Bazaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Hamzehgardeshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danial","family":"Shamshirian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Moosazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0580-000X","authenticated-orcid":false,"given":"Reza","family":"Alizadeh-Navaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"issue":"1","key":"7545_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330. \n                  https:\/\/doi.org\/10.3322\/caac.21442\n                  \n                .","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"7545_CR2","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/s1470-2045(13)70567-9","volume":"15","author":"L Fan","year":"2014","unstructured":"Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279\u201389. \n                  https:\/\/doi.org\/10.1016\/s1470-2045(13)70567-9\n                  \n                .","journal-title":"Lancet Oncol"},{"key":"7545_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/bctt.S176070","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Medical Press). 2019;11:151\u201364. \n                  https:\/\/doi.org\/10.2147\/bctt.S176070\n                  \n                .","journal-title":"Breast Cancer (Dove Medical Press)"},{"issue":"8433","key":"7545_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(85)92204-4","volume":"1","author":"L Tabar","year":"1985","unstructured":"Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the breast cancer screening working group of the Swedish National Board of Health and Welfare. Lancet (London, England). 1985;1(8433):829\u201332.","journal-title":"Lancet (London, England)"},{"key":"7545_CR5","doi-asserted-by":"publisher","first-page":"6509357","DOI":"10.1155\/2019\/6509357","volume":"2019","author":"L Zou","year":"2019","unstructured":"Zou L, Yu S, Meng T, Zhang Z, Liang X, Xie Y. A technical review of convolutional neural network-based mammographic breast Cancer diagnosis. Comput Math Methods Med. 2019;2019:6509357. \n                  https:\/\/doi.org\/10.1155\/2019\/6509357\n                  \n                .","journal-title":"Comput Math Methods Med"},{"issue":"3","key":"7545_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.critrevonc.2010.12.005","volume":"80","author":"CB Moelans","year":"2011","unstructured":"Moelans CB, de Weger RA, Van der Wall E, van Diest PJ. Current technologies for HER2 testing in breast cancer. Crit Rev Oncol Hematol. 2011;80(3):380\u201392. \n                  https:\/\/doi.org\/10.1016\/j.critrevonc.2010.12.005\n                  \n                .","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl","key":"7545_CR7","first-page":"S26","volume":"117","author":"IT Yeh","year":"2002","unstructured":"Yeh IT. Measuring HER-2 in breast cancer. Immunohistochemistry, FISH, or ELISA? Am J Clin Pathol. 2002;117(Suppl):S26\u201335.","journal-title":"Am J Clin Pathol"},{"issue":"4785","key":"7545_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235(4785):177\u201382.","journal-title":"Science"},{"issue":"8","key":"7545_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","volume":"20","author":"A Goldhirsch","year":"2009","unstructured":"Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319\u201329. \n                  https:\/\/doi.org\/10.1093\/annonc\/mdp322\n                  \n                .","journal-title":"Ann Oncol"},{"issue":"2","key":"7545_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/01.Mp.0000052102.90815.82","volume":"16","author":"M Bilous","year":"2003","unstructured":"Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16(2):173\u201382. \n                  https:\/\/doi.org\/10.1097\/01.Mp.0000052102.90815.82\n                  \n                .","journal-title":"Mod Pathol"},{"issue":"16","key":"7545_CR11","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1001\/jama.291.16.1972","volume":"291","author":"H Yaziji","year":"2004","unstructured":"Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al. HER-2 testing in breast cancer using parallel tissue-based methods. Jama. 2004;291(16):1972\u20137. \n                  https:\/\/doi.org\/10.1001\/jama.291.16.1972\n                  \n                .","journal-title":"Jama"},{"issue":"9","key":"7545_CR12","first-page":"2605","volume":"7","author":"JJCCR Baselga","year":"2001","unstructured":"Baselga JJCCR. Is circulating HER-2 more than just a tumor marker? Clin Cancer Res. 2001;7(9):2605\u20137.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"7545_CR13","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1200\/jco.2001.19.8.2334","volume":"19","author":"H Yamauchi","year":"2001","unstructured":"Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19(8):2334\u201356. \n                  https:\/\/doi.org\/10.1200\/jco.2001.19.8.2334\n                  \n                .","journal-title":"J Clin Oncol"},{"issue":"10","key":"7545_CR14","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1373\/49.10.1579","volume":"49","author":"WP Carney","year":"2003","unstructured":"Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum HER-2\/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 2003;49(10):1579\u201398.","journal-title":"Clin Chem"},{"issue":"2","key":"7545_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3816\/CBC.2004.n.014","volume":"5","author":"WP Carney","year":"2004","unstructured":"Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Monitoring the circulating levels of the HER2\/neu oncoprotein in breast cancer. Clin Breast Cancer. 2004;5(2):105\u201316.","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"7545_CR16","first-page":"4423","volume":"9","author":"BV Jensen","year":"2003","unstructured":"Jensen BV, Johansen JS, Price PA. High levels of serum HER-2\/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res. 2003;9(12):4423\u201334.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"7545_CR17","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1373\/clinchem.2006.067512","volume":"52","author":"SY Kong","year":"2006","unstructured":"Kong SY, Nam BH, Lee KS, Kwon Y, Lee ES, Seong MW, et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem. 2006;52(8):1510\u20135. \n                  https:\/\/doi.org\/10.1373\/clinchem.2006.067512\n                  \n                .","journal-title":"Clin Chem"},{"issue":"6","key":"7545_CR18","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/cncr.23689","volume":"113","author":"SM Ali","year":"2008","unstructured":"Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Kostler WJ, et al. Serum HER-2\/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer. 2008;113(6):1294\u2013301. \n                  https:\/\/doi.org\/10.1002\/cncr.23689\n                  \n                .","journal-title":"Cancer"},{"issue":"1","key":"7545_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4048\/jbc.2012.15.1.71","volume":"15","author":"DW Ryu","year":"2012","unstructured":"Ryu DW, Lee CH. Impact of serum HER2 levels on survival and its correlation with Clinicopathological parameters in women with breast Cancer. J Breast Cancer. 2012;15(1):71\u20138. \n                  https:\/\/doi.org\/10.4048\/jbc.2012.15.1.71\n                  \n                .","journal-title":"J Breast Cancer"},{"issue":"1","key":"7545_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.bbcan.2012.03.012","volume":"1826","author":"L Lam","year":"2012","unstructured":"Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012;1826(1):199\u2013208. \n                  https:\/\/doi.org\/10.1016\/j.bbcan.2012.03.012\n                  \n                .","journal-title":"Biochim Biophys Acta"},{"issue":"33","key":"7545_CR21","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1200\/jco.2007.14.2364","volume":"25","author":"L Harris","year":"2007","unstructured":"Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287\u2013312. \n                  https:\/\/doi.org\/10.1200\/jco.2007.14.2364\n                  \n                .","journal-title":"J Clin Oncol"},{"issue":"2","key":"7545_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1515\/CCLM.2007.034","volume":"45","author":"DA Olsen","year":"2007","unstructured":"Olsen DA, \u00d8stergaard B, Bokmand S, Wamberg PA, Jakobsen EH, Brandslund I. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin Chem Lab Med. 2007;45(2):177\u201382. \n                  https:\/\/doi.org\/10.1515\/CCLM.2007.034\n                  \n                .","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"7545_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/annonc\/mdm585","volume":"19","author":"V Ludovini","year":"2008","unstructured":"Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol. 2008;19(5):883\u201390. \n                  https:\/\/doi.org\/10.1093\/annonc\/mdm585\n                  \n                .","journal-title":"Ann Oncol"},{"issue":"2","key":"7545_CR24","first-page":"113","volume":"55","author":"E Papadopoulou","year":"2008","unstructured":"Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, et al. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Neoplasma. 2008;55(2):113\u201321.","journal-title":"Neoplasma"},{"issue":"3","key":"7545_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3233\/clo-2009-0468","volume":"31","author":"M Savino","year":"2009","unstructured":"Savino M, Parrella P, Copetti M, Barbano R, Murgo R, Fazio VM, et al. Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients. Cell Oncol. 2009;31(3):203\u201311. \n                  https:\/\/doi.org\/10.3233\/clo-2009-0468\n                  \n                .","journal-title":"Cell Oncol"},{"issue":"33","key":"7545_CR26","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1200\/jco.2008.21.1763","volume":"27","author":"RS Finn","year":"2009","unstructured":"Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, Koehler M. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol. 2009;27(33):5552\u20138. \n                  https:\/\/doi.org\/10.1200\/jco.2008.21.1763\n                  \n                .","journal-title":"J Clin Oncol"},{"issue":"6","key":"7545_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.breast.2010.05.012","volume":"19","author":"M Farzadnia","year":"2010","unstructured":"Farzadnia M, Meibodi NT, Shandiz FH, Mahmoudi M, Bahar MM, Memar B, et al. Evaluation of HER2\/neu oncoprotein in serum and tissue samples of women with breast cancer: correlation with clinicopathological parameters. Breast. 2010;19(6):489\u201392. \n                  https:\/\/doi.org\/10.1016\/j.breast.2010.05.012\n                  \n                .","journal-title":"Breast"},{"issue":"5","key":"7545_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1515\/cclm.2011.135","volume":"49","author":"JJ Lauterlein","year":"2011","unstructured":"Lauterlein JJ, Petersen ER, Olsen DA, Ostergaard B, Brandslund I. Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer. Clin Chem Lab Med. 2011;49(5):877\u201383. \n                  https:\/\/doi.org\/10.1515\/cclm.2011.135\n                  \n                .","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"7545_CR29","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00432-013-1411-7","volume":"139","author":"PD S\u00f8rensen","year":"2013","unstructured":"S\u00f8rensen PD, Jakobsen EH, Madsen JS, Petersen EB, Andersen RF, \u00d8stergaard B, et al. Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients. J Cancer Res Clin Oncol. 2013;139(6):1005\u201313. \n                  https:\/\/doi.org\/10.1007\/s00432-013-1411-7\n                  \n                .","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"7545_CR30","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1515\/cclm-2012-0488","volume":"51","author":"AC Pedersen","year":"2013","unstructured":"Pedersen AC, S\u00f8rensen PD, Jacobsen EH, Madsen JS, Brandslund I. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clin Chem Lab Med. 2013;51(7):1511\u20139. \n                  https:\/\/doi.org\/10.1515\/cclm-2012-0488\n                  \n                .","journal-title":"Clin Chem Lab Med"},{"key":"7545_CR31","doi-asserted-by":"publisher","unstructured":"Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Kahlert S, Stieber P. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. Clin Chim Acta. 2014;430:86\u201391. \n                  https:\/\/doi.org\/10.1016\/j.cca.2013.12.036\n                  \n                . Epub 2014 Jan 9. PMID: 24412321.","DOI":"10.1016\/j.cca.2013.12.036"},{"key":"7545_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cca.2014.11.001","volume":"440","author":"D Di Gioia","year":"2015","unstructured":"Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P. Serum HER2 in combination with CA 15\u20133 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta. 2015;440:16\u201322. \n                  https:\/\/doi.org\/10.1016\/j.cca.2014.11.001\n                  \n                .","journal-title":"Clin Chim Acta"},{"issue":"6","key":"7545_CR33","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.21873\/anticanres.11669","volume":"37","author":"M Banys-Paluchowski","year":"2017","unstructured":"Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, et al. Clinical relevance of serum HER2 and circulating tumor cell detection in metastatic breast cancer patients. Anticancer Res. 2017;37(6):3117\u201328. \n                  https:\/\/doi.org\/10.21873\/anticanres.11669\n                  \n                .","journal-title":"Anticancer Res"},{"key":"7545_CR34","doi-asserted-by":"publisher","unstructured":"Broughton MN, Westgaard A, Paus E, \u00d8ijordsbakken M, Henanger KJ, Naume B, et al. Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4). Tumor Biol. 2017;39(6). \n                  https:\/\/doi.org\/10.1177\/1010428317707436\n                  \n                .","DOI":"10.1177\/1010428317707436"},{"key":"7545_CR35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","volume":"5","author":"R Trevethan","year":"2017","unstructured":"Trevethan R. Sensitivity, specificity, and predictive values: foundations, Pliabilities, and pitfalls in research and practice. Front Public Health. 2017;5:307. \n                  https:\/\/doi.org\/10.3389\/fpubh.2017.00307\n                  \n                .","journal-title":"Front Public Health"},{"key":"7545_CR36","unstructured":"White S, Schultz T, Enuameh YAK. Synthesizing evidence of diagnostic accuracy. Philadelphia: Lippincott Williams & Wilkins; 2011."},{"issue":"1","key":"7545_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/PAP.0b013e3182026d72","volume":"18","author":"L Albarello","year":"2011","unstructured":"Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18(1):53\u20139. \n                  https:\/\/doi.org\/10.1097\/PAP.0b013e3182026d72\n                  \n                .","journal-title":"Adv Anat Pathol"},{"issue":"7","key":"7545_CR38","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/jco.1999.17.7.1974","volume":"17","author":"TW Jacobs","year":"1999","unstructured":"Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2\/neu in breast cancer. J Clin Oncol. 1999;17(7):1974\u201382. \n                  https:\/\/doi.org\/10.1200\/jco.1999.17.7.1974\n                  \n                .","journal-title":"J Clin Oncol"},{"issue":"6","key":"7545_CR39","first-page":"2356","volume":"6","author":"R Colomer","year":"2000","unstructured":"Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 2000;6(6):2356\u201362.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"7545_CR40","doi-asserted-by":"publisher","first-page":"R436","DOI":"10.1186\/bcr1020","volume":"7","author":"FJ Esteva","year":"2005","unstructured":"Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, et al. Clinical utility of serum HER2\/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 2005;7(4):R436\u201343. \n                  https:\/\/doi.org\/10.1186\/bcr1020\n                  \n                .","journal-title":"Breast Cancer Res"},{"issue":"3","key":"7545_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.seminhematol.2008.04.001","volume":"45","author":"PM Bossuyt","year":"2008","unstructured":"Bossuyt PM. Interpreting diagnostic test accuracy studies. Semin Hematol. 2008;45(3):189\u201395. \n                  https:\/\/doi.org\/10.1053\/j.seminhematol.2008.04.001\n                  \n                .","journal-title":"Semin Hematol"},{"issue":"7335","key":"7545_CR42","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1136\/bmj.324.7335.477","volume":"324","author":"JA Knottnerus","year":"2002","unstructured":"Knottnerus JA, van Weel C, Muris JW. Evaluation of diagnostic procedures. BMJ. 2002;324(7335):477\u201380. \n                  https:\/\/doi.org\/10.1136\/bmj.324.7335.477\n                  \n                .","journal-title":"BMJ"},{"issue":"4","key":"7545_CR43","first-page":"203","volume":"19","author":"AM \u0160imundi\u0107","year":"2009","unstructured":"\u0160imundi\u0107 AM. Measures of diagnostic accuracy: basic definitions. Ejifcc. 2009;19(4):203\u201311.","journal-title":"Ejifcc"},{"key":"7545_CR44","doi-asserted-by":"publisher","unstructured":"Luckmann R. Evidence-Based Medicine: How to Practice and Teach EBM, 2nd Edition: In: By David L. Sackett, Sharon E. Straus, W. Scott Richardson, William Rosenberg, and R. Brian Haynes, Churchill Livingstone, 2000. Vol. 16. Issue (3). 2001. p. 155\u2013156. \n                  https:\/\/doi.org\/10.1177\/088506660101600307\n                  \n                .","DOI":"10.1177\/088506660101600307"},{"issue":"7458","key":"7545_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/bmj.329.7458.168","volume":"329","author":"JJ Deeks","year":"2004","unstructured":"Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 2004;329(7458):168\u20139. \n                  https:\/\/doi.org\/10.1136\/bmj.329.7458.168\n                  \n                .","journal-title":"BMJ"},{"key":"7545_CR46","unstructured":"Guyatt G, Rennie D, Meade M, Cook D. Users\u2019 guides to the medical literature: a manual for evidence-based clinical practice. Chicago: American Medical Association; 2002."},{"issue":"2","key":"7545_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/1469-0691.12474","volume":"20","author":"MM Leeflang","year":"2014","unstructured":"Leeflang MM. Systematic reviews and meta-analyses of diagnostic test accuracy. Clin Microbiol Infect. 2014;20(2):105\u201313. \n                  https:\/\/doi.org\/10.1111\/1469-0691.12474\n                  \n                .","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"7545_CR48","doi-asserted-by":"publisher","first-page":"e0136322","DOI":"10.1371\/journal.pone.0136322","volume":"10","author":"K Zhang","year":"2015","unstructured":"Zhang K, Cui J, Xi H, Bian S, Ma L, Shen W, et al. Serum HER2 is a potential surrogate for tissue HER2 status in gastric Cancer: a systematic review and meta-analysis. PLoS One. 2015;10(8):e0136322. \n                  https:\/\/doi.org\/10.1371\/journal.pone.0136322\n                  \n                .","journal-title":"PLoS One"},{"key":"7545_CR49","doi-asserted-by":"publisher","first-page":"ix6","DOI":"10.1093\/annonc\/mdz416.019","volume":"30","author":"A Shamshirian","year":"2019","unstructured":"Shamshirian A, Heydari K, Aref AR, Alizadeh-Navaei R, Shamshirian D, Hamzehgardeshi Z, Moosazadeh M. 20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis. Ann Oncol. 2019;30:ix6. \n                  https:\/\/doi.org\/10.1093\/annonc\/mdz416.019\n                  \n                .","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07545-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T12:03:42Z","timestamp":1604405022000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07545-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7545"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07545-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-56350\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-56350\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"7 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study protocol has been registered in International Prospective Register of Systematic Reviews (PROSPERO) due to code CRD42019126703.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1049"}}